The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study

Current Medical Research and Opinion
T P DidangelosD T Karamitsos

Abstract

Metabolic syndrome (MetSyn) is associated with a marked increase in the risk of cardiovascular disease, especially in patients with type 2 diabetes mellitus (DM). To investigate the effect of orlistat plus hypocaloric diet (HCD) vs HCD alone on the cardiovascular risk profile in patients with both MetSyn (National Cholesterol Educational Program--NCEP--Adult Treatment Panel III definition) and type 2 DM. This was a prospective, multicentre, open-label, randomized, controlled study. One hundred and twenty-six patients, free of cardiovascular disease at baseline, were included in the final analysis. Ninety-four (73%) patients were treated with orlistat (360 mg/day) and HCD for a 6-month period, while 34 (27%) were on HCD alone. Analysis of covariance was used to assess differences between the treatment groups over time. Components of the MetSyn criteria assessed were: waist circumference; systolic and diastolic blood pressure; fasting glucose, triglycerides; high-density lipoprotein cholesterol (HDL-C) plus body mass index; glycosylated haemoglobin (HbA1C); homeostasis model for assessment of insulin resistance (HOMA) index; and total and low-density lipoprotein cholesterol (LDL-C). By protocol, all patients had MetSyn at baselin...Continue Reading

References

Jan 4, 1986·British Medical Journal·S H SaverymuttuJ D Maxwell
Oct 1, 1993·Annals of Internal Medicine·F X Pi-Sunyer
Jun 24, 1996·Archives of Internal Medicine·F GrodsteinM J Stampfer
Nov 26, 1998·American Journal of Epidemiology·M TrevisanA Menotti
Jan 26, 1999·JAMA : the Journal of the American Medical Association·M H DavidsonS B Heymsfield
May 4, 1999·Internal Medicine·T FunahashiY Matsuzawa
Jun 24, 2000·Diabetes·C T Montague, S O'Rahilly
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jul 18, 2001·Journal of Diabetes and Its Complications·J A PapadakisD P Mikhailidis
Jul 9, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·E BonoraM Muggeo
Sep 19, 2002·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·U L MathiesenG Bodemar
Dec 4, 2002·JAMA : the Journal of the American Medical Association·Hanna-Maaria LakkaJukka T Salonen
Apr 30, 2003·Diabetes·Charles M AlexanderUNKNOWN National Cholesterol Education Program (NCEP)
Jun 14, 2003·The American Journal of Cardiology·Nathan D WongG Rhys Williams
Aug 20, 2003·Diabetic Medicine : a Journal of the British Diabetic Association·P ZimmetK G M M Alberti
Dec 12, 2003·Angiology·Vasilios G AthyrosUNKNOWN GREACE Study Collaborative Group
Mar 26, 2004·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Vasilios G AthyrosUNKNOWN GREACE Study Collaborative Group

❮ Previous
Next ❯

Citations

Mar 3, 2006·Current Atherosclerosis Reports·Harold Bays, Carlos A Dujovne
Nov 2, 2006·Current Diabetes Reports·Juliet M Mancino
May 26, 2005·Current Treatment Options in Cardiovascular Medicine·Prakash C Deedwania, Natalia Volkova
Nov 30, 2010·Journal of the American Dietetic Association·Marion J FranzErica Gradwell
Feb 10, 2006·Disease Management : DM·W Dallas HallUNKNOWN African-American Lipid and Cardiovascular Council
May 20, 2008·Metabolic Syndrome and Related Disorders·I Jialal
Jan 26, 2012·Indian Journal of Endocrinology and Metabolism·Panagiotis Anagnostis
May 20, 2006·Current Medical Research and Opinion·Vasilios G AthyrosMoses S Elisaf
Aug 13, 2011·Nihon rinsho. Japanese journal of clinical medicine·Kazuwa Nakano
Mar 25, 2008·Journal of Diabetes and Its Complications·Apostolos I HatzitoliosDimitrios T Karamitsos
Oct 26, 2005·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·E N LiberopoulosM S Elisaf
Sep 9, 2015·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·N M AldekhailD S Morrison
Mar 21, 2006·Metabolism: Clinical and Experimental·Evanthia Diamanti-KandarakisAnastasios Kalofoutis
Nov 2, 2005·Expert Opinion on Pharmacotherapy·Robert H Nelson, John M Miles
Aug 9, 2007·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·V Giusti
Oct 13, 2016·Current Hypertension Reports·Sundararajan Srikanth, Prakash Deedwania
May 11, 2007·Expert Review of Cardiovascular Therapy·Cristina BianchiRoberto Miccoli
Mar 22, 2016·JRSM Cardiovascular Disease·Thang S Han, Mike Ej Lean
Sep 14, 2007·Clinical Pharmacology and Therapeutics·J A BatsisF Lopez-Jimenez
Aug 4, 2005·Expert Review of Cardiovascular Therapy·Katherine E Nori JanoszPeter A McCullough
Sep 8, 2006·Drugs·Sheridan Henness, Caroline M Perry
May 25, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·W Timothy GarveyUNKNOWN Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines
Jul 30, 2021·International Journal of Clinical Practice·Soheila NooriKhadijeh Mirzaei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.